Category: by author

UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Das, via UConn

The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das.

According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of interest for Das, a government-funded professor of surgery and director of the Cardiovascular Research Center, has been resveratrol, a substance in red wine that has allegedly been linked to improved cardiac health.

The university touted some of his early efforts in this field.

[Please also see our update posted Thursday.]

Here’s what the release has to say: Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case

Potti and colleagues retract 2008 JAMA paper

Anil Potti‘s retraction count is now eight with the withdrawal of a 2008 study in the Journal of the American Medical Association (JAMA).

Here’s the notice, which appeared online in JAMA sometime yesterday: Continue reading Potti and colleagues retract 2008 JAMA paper

Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits

The authors of a study in Urology that was at the center of two 2009 lawsuits brought by a company that funded the work have retracted the paper.

The idea behind the research — by Robert Getzenberg and colleagues at Johns Hopkins — was to find an alternative to the prostate specific antigen (PSA) test, which many urologists recommend, but which many groups — including the US Preventive Services Task Force — find wanting. The work gave rise to a company, Onconome, Science reported in a 2009 story about the lawsuits: Continue reading Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits

Seven retractions, a resignation, and lawsuit settlements haven’t stopped Anil Potti from publishing

“Neither snow nor rain nor heat nor gloom of night” keeps U.S. mail carriers from delivering your letters and packages, and neither seven retractions, nor being forced to resign, nor malpractice settlements (and an ongoing case) keeps former Duke oncologist Anil Potti from publishing papers.

Potti’s latest effort, “A Pathway-Based Approach to Identify Molecular Biomarkers in Cancer,” appeared  last month in the Annals of Surgical Oncology. The subject of the review is the same as many of his now-retracted papers, none of which are cited by the new paper. Continue reading Seven retractions, a resignation, and lawsuit settlements haven’t stopped Anil Potti from publishing

Blood retracts stem cell paper from Amy Wagers’ Harvard lab after 14 months of concern

More than 14 months after Blood issued a notice of concern about a paper by a Harvard stem cell scientist and her former post-doc, the journal has retracted the article.

Here’s the notice for the paper, “Osteolineage niche cells initiate hematopoietic stem cell mobilization,” by Shane Mayack and Amy Wagers: Continue reading Blood retracts stem cell paper from Amy Wagers’ Harvard lab after 14 months of concern

Chronic fatigue syndrome-XMRV paper retracted by Science, completely this time

The editors of Science have fully retracted a study they published in 2009 alleging a link between chronic fatigue syndrome (CFS) and the virus XMRV.

The notice begins with a nod to the reasons that the paper has already been partially retracted:

Science is fully retracting the Report “Detection of an infectious retrovirus, XMRV, in blood cells of patients with chronic fatigue syndrome” (1). Multiple laboratories, including those of the original authors (2), have failed to reliably detect xenotropic murine leukemia virus–related virus (XMRV) or other murine leukemia virus (MLV)–related viruses in chronic fatigue syndrome (CFS) patients. In addition, there is evidence of poor quality control in a number of specific experiments in the Report. Fig. 1, table S1, and fig. S2 have been retracted by the authors (3).

It also refers to evidence of image manipulation that was described by blogger Abbie Smith and then reported in the Chicago Tribune:

Continue reading Chronic fatigue syndrome-XMRV paper retracted by Science, completely this time

Another Hattori retraction over reused figure from cardiology pub

Another paper in Diabetologia by Yoshiyuki Hattori has been retracted for image duplication, marking the second of his articles in the journal to be pulled for that reason.

The notice for the article, “A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells,” states: Continue reading Another Hattori retraction over reused figure from cardiology pub

Bulfone-Paus retraction count grows to 13 with one in Transplantation

Silvia Bulfone-Paus, the Borstel Institute researcher who was forced to step down as institute director and has already retracted 12 papers, has retracted another, this one in Transplantation. Here’s the text of the notice: Continue reading Bulfone-Paus retraction count grows to 13 with one in Transplantation

Corrections in PLoS One, Nature Medicine for Zhiguo Wang, and details about Montreal Heart Institute investigation

via Wikimedia

PLoS One and Nature Medicine have issued corrections for papers by Zhiguo Wang, the former Montreal Heart Institute researcher who resigned in September following an investigation into image manipulation in his lab. 

In September, PLoS One told us that they were investigating the paper. Here’s the text of the correction for “Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of Ether À Go-Go K+ Channel:” Continue reading Corrections in PLoS One, Nature Medicine for Zhiguo Wang, and details about Montreal Heart Institute investigation

Anil Potti reprimanded by North Carolina state medical board, as lawsuit settlements surface

There are a few new developments in the case of Anil Potti, the former Duke oncologist who resigned amidst an investigation into clinical trials he was running — and has been forced to retract seven papers, at last count.

Over the weekend, The Cancer Letter, which has been out front on this case, noted that the North Carolina Medical Board reprimanded Potti late last month. A reprimand carries no sanctions, but is entered into a physician’s public record. According to the consent decree: Continue reading Anil Potti reprimanded by North Carolina state medical board, as lawsuit settlements surface